** Shares of weight-loss drug developer of Veru VERU.O rise 46% to 74 cents premarket
** VERU says combination of its experimental drug, enobosarm, and semaglutide resulted in fewer gastrointestinal side effects such as diarrhea and nausea in mid-stage trial, compared with semaglutide alone
** Combo drug met main goal of mid-stage trial earlier this year
** Patients taking enobosarm 3mg with semaglutide saw 99% loss of fat while preserving lean muscle mass, co says
** VERU has requested meeting with U.S. FDA to discuss next steps for enobosarm, including potential late-stage trial
** As of last close, stock down 21.8% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。